Clinical trial · Interventional
Impact of Acetazolamide in Reducing Referred Postoperative Pain
Impact of Acetazolamide in Reducing Referred Postoperative Pain After Robotic Assisted Laparoscopic Prostatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Robotic assisted laparoscopic prostatectomy (RALP) is the standard treatment for prostate cancer, due to the benefits of decreased blood loss and length of stay.The procedure involves removing a man's prostate using a minimally invasive robotic approach under the guidance of a surgeon. In order to gain sufficient access, carbon dioxide (CO2) is used to fill the surgical space in a process termed insufflation. Carbon dioxide is a mainstay in laparoscopic procedures because it is cost-effective, noncombustible and readily excreted via the respiratory system in healthy patients. Insufflation with CO2, however, has been linked to post-operative referred pain secondary to peritoneal acidosis.This acidosis is suspected to be due to the formation of carbonic acid from the CO2 insufflation.Peritoneal acidosis, and its associated post-operative referred pain, may not be adequately treated with the current standard pain control regimen.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Men | Multiple Endocrine Neoplasia | ALIAS | 0.90 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acetazolamide | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Acetazolamide
- description
- Group 1 (acetazolamide): Patients undergoing RALP with the peri-operative use of one-time 250 mg dose of acetazolamide
- interventionNames
- Drug: Acetazolamide
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Visual Analogue Scale (VAS) 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his pain.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: • Male patients ≥18 years of age undergoing robotic-assisted prostatectomy Exclusion Criteria: * Patients with renal insufficiency with serum creatinine \>2.0 mg/dl * Patients with renal transplant * Patients with pre-existing metabolic acidosis * Patients with chronic obstructive pulmonary disease * Patients with hepatic disease * Patients with central nervous system disorders * Patients with hematological disease history * Patients with pre-existing electrolyte abnormalities * Patients with hypovolemia * Patients with lithium or diuretic usage * Patients with sulfonamides allergy * Patients with American Society of Anesthesiologists physical status 4 or 5
References
Publications (0)
Data not yet available